Clinical Trial

Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3205 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3205 capsules.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-21
Trial Details
NCT Number NCT07482592
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Advanced Malignant Cancer
Enrollment 156 participants
Start Date 2026-04-15
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-20